Congress Eyes Pentagon Study on Psilocybin for Military PTSD Treatment
Bipartisan bill would mandate Defense Department review of psychedelic therapy research for servicemembers, signaling growing federal acceptance of alternative treatments.
Congressional lawmakers introduce bipartisan legislation requiring the Pentagon to evaluate psilocybin therapy research for military personnel suffering from PTSD. The Veterans and Servicemembers PTSD Emerging Treatment Review Act, sponsored by Rep. Abe Hamadeh (R-AZ), represents another step toward federal recognition of psychedelic medicine's therapeutic potential.
The bill arrives as psychedelic companies face mounting pressure to demonstrate clinical efficacy and navigate complex regulatory pathways. COMPASS Pathways (NASDAQ: CMPS) trades near 52-week lows despite advancing its psilocybin program through Phase III trials, while Cybin (NYSE: CYBN) struggles with investor confidence amid delayed timelines. Federal endorsement through military research could provide crucial validation for the sector.
Military applications offer psychedelic companies a potentially lucrative and politically palatable market entry point. PTSD affects approximately 11-20% of veterans who served in Iraq and Afghanistan, creating substantial demand for effective treatments. Current pharmaceutical options show limited success rates, leaving room for breakthrough therapies to capture significant market share within the Department of Veterans Affairs healthcare system.
The legislation reflects growing bipartisan support for psychedelic research, following FDA breakthrough therapy designations for MDMA and psilocybin in recent years. State-level psilocybin legalization in Oregon and Colorado demonstrates shifting public attitudes, while cities across multiple states decriminalize possession. This regulatory momentum creates favorable conditions for psychedelic biotechnology companies seeking investment and partnership opportunities.
Pentagon involvement would accelerate research timelines and provide federal funding for clinical studies, potentially reducing development costs for private companies. Military medical research historically drives innovation adoption in civilian healthcare markets, suggesting successful PTSD applications could expand into broader mental health treatment categories. The bill positions psychedelic therapy within mainstream medical discourse rather than recreational drug policy debates, supporting long-term industry legitimacy and growth prospects.